Experience
Jackpocket Reaches Agreement to Be Acquired by DraftKings for $750 Million
February 15, 2024
Cooley advised Jackpocket, the first licensed third-party lottery courier app in the US, on its definitive agreement to be acquired by DraftKings for $750 million.
Related contacts
Related Practices & Industries
Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179
February 14, 2024
Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.
Related contacts
Related Practices & Industries
Rubicon Technology Partners Announces Strategic Majority Investment in Vimly Benefit Solutions
February 13, 2024
Cooley advised Rubicon Technology Partners – a Boulder, Colorado-based private equity firm focused exclusively on investing in and growing software companies – on its majority strategic investment in Vimly Benefit Solutions, a leader in the benefits administration space.
Related contacts
Related Practices & Industries
Gracell Biotechnologies Agrees to Acquisition by AstraZeneca for up to $1.2 Billion
December 26, 2023
Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.
Related contacts
Related Practices & Industries
RayzeBio Signs Approximately $4.1 Billion Acquisition Agreement With Bristol Myers Squibb
December 26, 2023
Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.